Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.

Halon A, Materna V, Donizy P, Matkowski R, Rabczynski J, Lage H, Surowiak P.

Arch Gynecol Obstet. 2013 Mar;287(3):563-70. doi: 10.1007/s00404-012-2589-7. Epub 2012 Nov 8.

2.

ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome.

Maciejczyk A, Jagoda E, Wysocka T, Matkowski R, Györffy B, Lage H, Surowiak P.

Pathol Oncol Res. 2012 Apr;18(2):331-42. doi: 10.1007/s12253-011-9449-9. Epub 2011 Oct 11.

PMID:
21986666
3.

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H.

Clin Cancer Res. 2006 Dec 1;12(23):7149-58.

4.

Argyrophilic proteins of nucleolar organizer regions (AgNORs) in fallopian tube carcinomas.

Rabczyńiski JK, Kochman AT, Karmowski A, Woźniak ZM, Bronowicz A, Terpiłowski L.

Clin Exp Obstet Gynecol. 2000;27(2):125-8.

PMID:
10968353
5.

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, Wiemann MC.

Eur J Gynaecol Oncol. 2004;25(2):165-8.

PMID:
15032273
6.

[Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].

Katsaros D, Fracchioli S, Arts HJ, de Vries EG, Danese S, Richiardi G, Arisio R, Gordini G, Van der Zee AG, Suurmeijer AJ, Massobrio M.

Minerva Ginecol. 1999 Dec;51(12):463-70. Italian.

PMID:
10767994
7.

Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.

Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y.

Oncol Rep. 2011 Apr;25(4):1131-8. doi: 10.3892/or.2011.1151. Epub 2011 Jan 18.

PMID:
21249319
8.

Primary fallopian tube carcinoma. Histopathology of 46 cases.

Rabczyński J, Ziółkowski P, Kochman A, Górzyńska E.

Pol J Pathol. 1998;49(4):285-92.

PMID:
10323083
9.

Expression of insulin-like growth factor-1 receptors, Wilm's tumor-1 protein, c-kit and p16 in primary fallopian tube carcinoma in diabetic patients.

Al-Salam S, Alashari M, Ghazal-Aswad S.

Arch Gynecol Obstet. 2008 May;277(5):449-55. Epub 2007 Oct 31.

PMID:
17972088
10.

Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ.

Clin Cancer Res. 1999 Oct;5(10):2798-805.

11.

Carcinoma of the fallopian tube.

Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM.

Cancer. 2000 Nov 15;89(10):2076-84.

PMID:
11066048
12.

Prognostic significance of tumor angiogenesis in primary fallopian tube cancer.

Bancher-Todesca D, Rosen A, Graf A, Wasicky R, Hohlagschwandtner M, Rebhandl W, Heinze G, Breitenecker G, Gitsch G, Obermair A.

Cancer Lett. 1999 Jul 1;141(1-2):179-86.

PMID:
10454260
13.

PCNA and laminin as prognostic factors in primary Fallopian tube carcinoma.

Hałoń A, Rabczyński J.

Folia Morphol (Warsz). 2003 Nov;62(4):475-8.

PMID:
14655145
14.

[Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].

Sedláková I, Laco J, Tošner J, Špaček J.

Ceska Gynekol. 2015 Dec;80(6):405-13. Czech.

PMID:
26741154
15.

MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR, Defazio A.

Gynecol Oncol. 2006 Feb;100(2):239-46. Epub 2005 Oct 5.

PMID:
16213010
16.

Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.

Urabe R, Hachisuga T, Kurita T, Kagami S, Kawagoe T, Matsuura Y, Shimajiri S.

J Obstet Gynaecol Res. 2014 Mar;40(3):812-9. doi: 10.1111/jog.12215. Epub 2013 Nov 18.

PMID:
24246002
17.

The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.

Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B.

Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76.

PMID:
12060448
18.

Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas.

Ruggeri RM, Sciacchitano S, Vitarelli E, Trimarchi F, Barresi G, Trovato M.

Arch Pathol Lab Med. 2006 Jul;130(7):1014-9. Erratum in: Arch Pathol Lab Med. 2006 Dec;130(12):1750.

PMID:
16831027
19.

A case report: rare case of primary transitional cell carcinoma of the fallopian tube.

Takeuchi S, Hirano H, Ichio T, Taniguchi H, Toyoda N.

J Obstet Gynaecol Res. 1999 Feb;25(1):29-32.

PMID:
10067010
20.

Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.

Rabczyński J, Ziółkowski P.

Pathol Oncol Res. 1999;5(1):61-6. Review.

Supplemental Content

Support Center